Lung Neoplasm Malignant Clinical Trial
Official title:
The Safety and Feasibility of Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Locally Advanced Resectable Non-Small Cell Lung Cancer
Neoadjuvant chemotherapy followed by surgery has been recommended as the standard treatment for locally advanced and resectable non-small cell lung cancer (NSCLC). However, its efficacy remains to be improved. Drugs targeting PD-1/PD-L1 pathway have been proven to be effective for late-stage NSCLC, and anti-angiogenesis agents targeting VEGF (bevacizumab) has also been used for the first line treatment of advanced or metastatic NSCLC. Therefore, we conduct this single-arm clinical trial, which aims to investigate the safety and feasibility of neoadjuvant sintilimab combined with bevacizumab and chemotherapy followed by surgery in treating locally advanced and resectable NSCLC.
Lung cancer is one of the most common malignancies around the world. Neoadjuvant chemotherapy followed by surgery has been recommended as the standard treatment for locally advanced and resectable non-small cell lung cancer (NSCLC). However, its efficacy remains to be improved. Bevacizumab targeting VEGF is a widely used antitumor drugs in different types of malignancies, including late-stage NSCLC. Immune checkpoint inhibitor (ICI) targeting PD-1 has also been confirmed to be effective in NSCLC patients. Therefore, we conduct this prospective single-arm clinical trial, to investigate the safety and feasibility of neoadjuvant sintilimab (ICI targeting PD-1) combined with bevacizumab and chemotherapy followed by surgery in treating locally advanced and resectable NSCLC. Twenty patients with stage II-IIIA NSCLC will be enrolled. And the primary endpoint of this study is the safety of this newly developed neoadjuvant treatment. The secondary endpoints are feasibility, radiological response and rate of major pathological response. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05890872 -
Aliya™ Pulsed Electric Fields (PEF) for Advanced Cancer
|
N/A | |
| Recruiting |
NCT05974475 -
MONDRIAN: Multi-omics Integrative Modelling for Stereotactic Body Radiotherapy in Early-stage Non-small Cell Lung Cancer
|
||
| Recruiting |
NCT06079970 -
Confocal Laser Endomicroscopy VERification
|
N/A | |
| Recruiting |
NCT04778826 -
Immune Response Following Lobectomy Along With or Without Bilateral Transcervical Mediastinal Lymphadenectomy
|
N/A | |
| Suspended |
NCT04036721 -
Coorticosteroid Regimen in Patients With Anti-PD-1/PD-L1 Induced Pneumonitis
|
Phase 4 | |
| Completed |
NCT03352245 -
Feasibility of an Activity Regimen in Patients With Advanced Stage Lung Cancer
|
N/A | |
| Completed |
NCT03834116 -
Resistance Inspiratory Muscle Training for Patients With Thoracic Malignancies
|
N/A | |
| Completed |
NCT03824977 -
Prognostic Value of the 6-minute Stepper Test in Non-small Cell Lung Cancer Surgery
|
||
| Terminated |
NCT02985203 -
Oral Navelbine and Cisplatin Followed by Metronomic Oral Navelbine in Non-Small Cell Lung Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT05241873 -
(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
|
Phase 1/Phase 2 | |
| Completed |
NCT05404022 -
Feasibility Trial of a Personalised Nutrition and Activity Programme for People With Lung Cancer Over 65 Years
|
N/A | |
| Not yet recruiting |
NCT05414188 -
Beneficial Effect of Pulmonary Rehabilitation in Lung Cancer Patients Receiving Radiation Therapy
|
N/A | |
| Recruiting |
NCT03525782 -
Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC
|
Phase 1/Phase 2 | |
| Completed |
NCT04059887 -
Evaluation of Blood TMB for the Efficacy of Atezolizumab [BUDDY]
|
Phase 4 | |
| Terminated |
NCT05013554 -
Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors
|
Phase 1 |